KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Net: 2015-2024

Historic Receivables - Net for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Dec 2024 value amounting to $25.0 million.

  • CRISPR Therapeutics AG's Receivables - Net fell 87.50% to $25.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $25.0 million, marking a year-over-year decrease of 87.50%. This contributed to the annual value of $25.0 million for FY2024, which is 87.50% down from last year.
  • As of Q4 2024, CRISPR Therapeutics AG's Receivables - Net stood at $25.0 million, which was down 87.50% from $200.0 million recorded in Q4 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Receivables - Net peaked at $200.0 million during Q4 2023, and registered a low of $33,000 during Q2 2020.
  • In the last 3 years, CRISPR Therapeutics AG's Receivables - Net had a median value of $12.6 million in 2022 and averaged $49.2 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Receivables - Net crashed by 99.40% in 2021, and later skyrocketed by 105,960.61% in 2023.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Receivables - Net stood at $144,000 in 2020, then surged by 111.81% to $305,000 in 2021, then crashed by 67.76% to $49,000 in 2022, then surged by 105,960.61% to $200.0 million in 2023, then plummeted by 87.50% to $25.0 million in 2024.
  • Its Receivables - Net was $25.0 million in Q4 2024, compared to $200.0 million in Q4 2023 and $70.0 million in Q2 2023.